论文部分内容阅读
目的:探讨辛伐他汀在治疗血脂正常的急性冠脉综合征(ACS)中的可行性、有效性和安全性。方法:239例ACS患者,随机分为试药组(n=115)和对照组(n=124),试药组在对照组常规治疗的基础上加用辛伐他汀口服20 mg/d治疗。出院后继续口服辛伐他汀6个月。所有患者进行随访。观察两组病例用药前后主要心血管事件的发生率。结果:用药6个月后试药组发生心血管事件18例(15.6%),对照组发生心血管事件49例(39.5%),两组间的差异具有显著性意义(P<0.05);试药组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及C-反应蛋白(CRP)水平,与治疗前比较显著降低,差异具有显著性意义(P<0.05)。两组不良反应比较差异无显著性意义。结论:辛伐他汀治疗血脂正常的ACS疗效确切,无明显副作用。
Objective: To investigate the feasibility, efficacy and safety of simvastatin in the treatment of acute coronary syndrome (ACS) with normal blood lipids. Methods: A total of 239 patients with ACS were randomly divided into the test group (n = 115) and the control group (n = 124). The test group was treated with 20 mg / d of simvastatin orally on the basis of routine treatment in the control group. After discharge from the hospital continue to simvastatin 6 months. All patients were followed up. The incidence of major cardiovascular events before and after treatment was observed in two groups of patients. Results: Six months after treatment, 18 cases (15.6%) had cardiovascular events in the test group and 49 cases (39.5%) had cardiovascular events in the control group, with significant difference (P <0.05). The levels of serum total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) and C-reactive protein (CRP) in the drug group were significantly lower than those before treatment, with significant difference (P <0.05). No significant difference between the two groups of adverse reactions. Conclusion: The effect of simvastatin in the treatment of normal blood lipids is effective and has no obvious side effects.